Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. - Wikidata - thesis-toulmin - TriplyDB

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

http://www.wikidata.org/entity/Q33286242

about

YKL-40 tissue expression and plasma levels in patients with ovarian cancer Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells Immunotherapy for cancer in the central nervous system: Current and future directions Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma Molecular heterogeneity in glioblastoma: potential clinical implications Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.Immunohistochemical assessment of protein phosphorylation state: the dream and the reality Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling.Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy.Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.History and current state of immunotherapy in glioma and brain metastasis.An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation.Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab.Temozolomide in malignant glioma The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.EGFR gene overexpression retained in an invasive xenograft model by solid orthotopic transplantation of human glioblastoma multiforme into nude mice.High-throughput screening identifies aclacinomycin as a radiosensitizer of EGFR-mutant non-small cell lung cancer DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro.Immunotherapy for malignant glioma Forced dimerization increases the activity of ΔEGFR/EGFRvIII and enhances its oncogenicity.Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.Expression of EGFRvIII in glioblastoma: prognostic significance revisited Characterization of RNA from Exosomes and Other Extracellular Vesicles Isolated by a Novel Spin Column-Based Method Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.Extracellular membrane vesicles and immune regulation in the brain.

P2860

Q21260376-841774AF-F70D-4302-96CF-EA96235DD369 Q24614672-6B16C59F-85E4-4B1D-8EE7-42244AC42B59 Q24656942-2E7415E4-2972-4F98-A633-6EDA014A4674 Q26750765-5240918C-0C6B-4831-9FDE-126A4889B153 Q26998561-5F26039F-8381-4BBC-A60E-505072F4B525 Q27015045-F4851409-B789-447A-8371-042739C94E3A Q27024830-C97AE413-920D-4CD4-9011-BAC2FF6CADAA Q27853118-580EDB91-46FD-4483-BF1D-42ABC6EB502A Q27853219-798F364C-EA0C-4981-8630-B42C6B645745 Q28087306-9AB22A32-6F87-40A2-9FDE-A0A64F96684F Q28088605-2111B296-9061-4BE7-BA38-2CCCFAC5ECE8 Q30416775-E1350BEC-4F46-4AA4-B2C0-71C43A6F69C1 Q30441231-BAAC7B72-60E8-4F5F-B952-9F8066DC9AF5 Q30588679-D3B4013B-45F0-4798-9007-135EF0887711 Q30872679-0874CFB9-4F27-4118-B982-5153D0E16DB4 Q33346827-852B048B-D7F6-4442-A125-0184039F2200 Q33551268-5BC7E750-9408-4C16-92BD-A1E92054A5F4 Q33644407-3E8F63C0-C0F0-45F3-8EB5-740D5819C3CC Q33656811-05D1734F-EBF5-4106-9ECF-29A906F305FB Q33665884-E93B0305-A27C-4BA8-A0CF-B7A2F2EE52DD Q33719157-62C4149F-0026-4501-A35D-F52C5EC991FA Q33746514-F7CFFCC3-E3D8-407A-A8A3-D967491973F8 Q33880422-5B006A7B-B0C8-4F79-A63B-18AB8A9EA837 Q33925544-76E07790-24E0-41D5-9538-45EB3FD79D89 Q34488771-69F48AC5-5E7D-4049-B5ED-6C45AE94CF7B Q34586272-5AFC7FAD-3119-4279-BA70-ED839ED60AC2 Q34623633-D5023196-2C65-4ADE-97DB-61110126F5DD Q34639763-F4980225-03BD-4BB2-9953-FBB936007D8C Q34661966-B1623134-35DF-43FC-BF9A-716A3A04BA63 Q34752832-6BFB88C0-F185-489C-ACC9-7A425241737E Q35059032-355A9F19-CF64-482E-AF86-31C6084E57E9 Q35114086-297313D6-4CC4-4672-A389-2B9235865F8F Q35218835-9A2603A0-1EC9-412B-9570-AE2E4C4090D3 Q35419401-0EFD5BEA-F9E2-4752-B942-F1F1157F2B4E Q35669708-61DA261F-9BC6-474C-B357-1452AD4B0E1A Q35758580-BD6EB8D0-CFBC-45C9-A868-C320CD0FC3F3 Q35788884-758F4D67-C69D-494D-926A-B31839331280 Q35886554-74C68950-34ED-4EB3-BBF0-5EF32183C841 Q35914541-65A6894C-55A6-4C9D-A281-7BE1778812D2 Q35924477-6931E4C1-0ED6-4D5F-9188-57A1602DC405

P2860

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

http://www.wikidata.org/entity/Q33286242

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Epidermal growth factor recept ...... inct subtypes of glioblastoma.

@ast

Epidermal growth factor recept ...... inct subtypes of glioblastoma.

@en

type

label

Epidermal growth factor recept ...... inct subtypes of glioblastoma.

@ast

Epidermal growth factor recept ...... inct subtypes of glioblastoma.

@en

prefLabel

Epidermal growth factor recept ...... inct subtypes of glioblastoma.

@ast

Epidermal growth factor recept ...... inct subtypes of glioblastoma.

@en

P1433

Q33286242-02F5C852-9F3B-469A-986E-EFF3AB6ABA35

P1476

Q33286242-52D64006-AE75-4583-888B-612FAAF4EF3F

P2093

Q33286242-0121F3B3-EEE9-4338-9AA8-44DE08FD2A32

Q33286242-03EA7064-AC9A-4C59-8FAB-736CA9031B2B

Q33286242-2264565D-AC73-42C7-8E06-D655CC25E318

Q33286242-2DD4DDAC-2673-4671-894C-6832E7D74A87

Q33286242-3FCB1D26-B131-40F5-B94A-6AD2621879FA

Q33286242-423AC531-A455-4918-9388-D0615902E007

Q33286242-69487C01-C245-4605-8596-45C119EFC926

Q33286242-6C10FD2D-392D-42B0-B711-1C91FCB4D5C5

Q33286242-6E1048CF-6951-4EA9-B14E-651335118D4A

Q33286242-85FCD126-1399-4160-B1E8-CBB18525BB14

P304

Q33286242-D2B8CF9D-9DCB-4F54-8A89-76684D1E7D83

P31

Q33286242-9F0D32FC-5C11-4D3C-9ACC-B0F9B777103D

P356

Q33286242-DAD2D809-91D9-46EB-B786-E8DB8ABA0834

P407

Q33286242-EDF3A7F7-5AA4-419C-8164-5EC51FC8CA02

P433

Q33286242-D3051271-BDB0-4B13-84D9-6CF8E598059D

P478

Q33286242-AD832734-BC47-4319-AA59-52D1DAFF9FD7

P577

Q33286242-BFC0E20B-8010-42A9-A391-83F51482EC2F

P698

Q33286242-552DBD82-C33D-45AC-892F-F690C19965F9

P356

JCO.2006.08.0705

P1433

Journal of Clinical Oncology

P1476

Epidermal growth factor recept ...... inct subtypes of glioblastoma.

@en

P2093

Alfred F Furth

http://www.w3.org/2001/XMLSchema#string

Amy B Heimberger

http://www.w3.org/2001/XMLSchema#string

C David James

http://www.w3.org/2001/XMLSchema#string

Christopher E Pelloski

http://www.w3.org/2001/XMLSchema#string

Dima Suki

http://www.w3.org/2001/XMLSchema#string

E Lin

http://www.w3.org/2001/XMLSchema#string

Erik P Sulman

http://www.w3.org/2001/XMLSchema#string

Fred G Barker

http://www.w3.org/2001/XMLSchema#string

Howard Colman

http://www.w3.org/2001/XMLSchema#string

J Matthew McDonald

http://www.w3.org/2001/XMLSchema#string

P304

2288-2294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.08.0705

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2007-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17538175

http://www.w3.org/2001/XMLSchema#string